Catalyst Pharmaceuticals, Inc. (CPRX) on Decifer

Decifer ranks CPRX number 167 of 265 tracked names on durable business quality.

Why it ranks here

• It earns strong returns on the money it puts to work, around 20% and it turns most of its profit into real cash.
• Revenue is growing about 20% a year and profits grew 27% over the past year.
• It keeps a high share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power, with profitability widening as it grows.
• and has the balance sheet to fund its growth.
• And it returns cash to shareholders.
• Strong returns near 20 percent and revenue up 20 percent with momentum at 16 out of 35 have no worldview growth role to buy behind now.

The current read

The evidence on CPRX lines up on the supportive side: a live market force supports this name through its theme connection. The independent signals we track are telling the same story.

Themes

• Next-Gen Genetic & RNA/Antibody Therapeutics: Platform breakthroughs in RNA interference, redosable gene therapy and antibody engineering are converting once-undruggable and orphan targets into commercial therapies.

Read the full CPRX research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.